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Summary: In a study designed to measure lipoprotein(a), cholesterol, cholesterol fractions and triacylglycerols in
serum 4004 hospitalised individuals aged between 18 and 100 years were examined.
Lipoprotein(a) was determined in 1313 patients (438 males, 875 females) aged 18-59 years and 489 patients (234
males, 255 females) aged 60—100 years. Cholesterol, cholesterol fractions and triacylglycerols were determined in
a further 2037 patients (1084 males, 953 females) aged 18 to 100 years, for whom a lipid-status request had
been made.
Lipoprotein(a) concentrations in 619 females measured directly postpartum were not significantly different from
aged-matched female in-patients (n = 104) and age-matched female hospital staff (n = 114). Lipoprotein(a) concen-
trations in women (n = 77) aged 30—74 undergoing chronic haemodialysis were significantly higher (p < 0.001)
than in men (n = 95) of the corresponding age group.
Median lipoprotein(a) serum concentrations showed a peak between 60—69 years in both men and women, i. e. at
times of reported increased cardiovascular disease in both sexes. The lipoprotein(a) levels found in old age are
comparable with those found in children and adolescents.
The lipoprotein(a) patient group was assessed according to age and clinic. Eight groups of patients were analysed.
The maternity patients were significantly younger (median age 26 a) than the other seven groups (p < 0.05-
< 0.01), the hospital employees (median age 31 a) attending the annual check-up being younger than the remaining
six groups (p < 0.01).
Lipoprotein(a) concentrations were marginally higher (p = 0.05) in the dialysis patients, when compared with those
on internal medical wards.
Of the 'traditional' lipid analytes, the ratio LDL-cholesterol : HDL-cholesterol was of interest, being significantly
higher in males aged 70—79 years of age, when compared with males under 30 years of age. Triacylglycerols were
higher in men aged between 30 and 59 years (p = 0.05-< 0.01).
The relationship between median analyte concentration and age was different for lipoprotein(a) than for the ratio
LDL-cholesterol : HDL-cholesterol and triacylglycerols, thus further supporting the fact that lipoprotein(a) may be
an independent risk factor for the development of atherosclerotic disease.
Introduction
The present trend toward establishment of reference from healthy and sick individuals, especially for labo-
intervals for hospitalised patients, although controver- ratory analytes, in the management and diagnosis of
sial (1, 2), emphasises the need for reliable data both disease.
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The present article presents data from a population of
patients aged between 18 and 100 years who were ad-
mitted to hospital for a variety of reasons. Specific
groups studied included patients undergoing chronic
haemodialysis, women directly postpartural, as well as
patients from medical, surgical, urological and psycho-
logical wards and hospital employees attending an an-
nual check-up. Lipoprotein(a) concentrations were mea-
sured in serum or plasma. In addition, cholesterol, LDL-
cholesterol, HDL-cholesterol and triacylglycerols, were
measured in another group of patients who had lipid-
requests, with the aim of establishing age- and sex-de-
pendent concentration ranges for both groups.
The German Federal Statistics Bureau (3) has reported a
net increase in serum cholesterol levels in elderly pa-
tients, concomitant with a reduction in the mortality
rates in the ICD 9 categories 410-414, i.e. deaths due
to cardiac disease. As cholesterol is linked with athero-
sclerotic disease, it was of interest to study the concen-
trations of this analyte, (as total cholesterol, high- and
low-density lipoprotein cholesterol and the ratio be-
tween low density and high density lipoprotein choles-
terol), as well as lipoprotein(a), as both are ascribed ma-
jor roles in the development of cardiovascular disease.
Materials and Methods
Patients
A total of 4004 persons was included in this study which was
carried out between July 1993 and May 1995. The distribution of
those studied was: 1313 patients between 18 and 59 years of age
(438 males, 875 females) and 489 patients (234 males, 255 fe-
males) of age between 60 and 100 years (median age: males -
72a [range 60-100 a], females - 75 a [range 60-93 a]) who un-
derwent hospital treatment were admitted to the study for lipopro-
tein(a) determinations. Healthy hospital employees (n = 165) at-
tending a routine check-up (51 males (median age 32 a) and 114
females (median age 31 a), 619 mothers directly after the birth of
a child (median age 26 a) and 214 dialysis patients before dialysis
(114 males, median age 53 a, 100 females, median age 62 a) were
examined as separate groups.
In addition, the age of the patients and their lipoprotein(a) concen-
trations were analysed according to the clinic in which the treat-
ment was being given. Eight groups were formed: medical, surgi-
cal, urological, psychiatric, maternity, haemodialysis, varia (clinics
with too few patients for statistical analysis) and hospital staff at-
tending an annual check-up.
The measurement of cholesterol, cholesterol fractions and triacyl-
glycerols was performed in 693 patients with lipid-electrophoresis
requests (378 males [median age 5la] and 315 females [median
age 58 a]) and 1344 lipid requests (247 males under 60 a [median
age 51 a], 171 females under 60 a [median age 48 a], 459 males
over 60 a [median age 66 a] and 467 females over 60 a [median
age 68 a]). These groups were analysed separately from the lipo-
protein(a) patients.
Assays used
Lipoprotein(a) was determined by means of immunoluminometric
assay using two polyclonal antibodies directed against apolipopro-
tein(a) as already published in this journal (4, 5). One lot of rea-
gents was used throughout the study, so that consistency of results
is guaranteed.
Cholesterol was measured using the cholesterol oxidase-peroxi-
dase-phenol-4-aminoantipyrine (CHOD-PAP) method (Boehringer
Mannheim, Mannheim, Germany), which makes use of the Trinder
reaction (6) to generate a colour in the visible spectrum.
• r
HDL-cholesterol was analysed enzymatically as above after treat-
ment of the serum with freshly prepared magnesium chloride-phos-
photungstic acid reagent, (quantitative precipitation of chylo-
microns, VLDL-cholesterol, LDL-cholesterol and lipoprotein(a))
and subsequent determination of cholesterol in the supernatant af-
ter centrifugation.
LDL-cholesterol was measured enzymatically as above after pre-
cipitation with dextran sulphate, which was supplied ready to use
from Immuno, Heidelberg, Germany. The supernatant containing
the HDLrcholesterol and VLDL-cholesterol was measured, the
LDL-cholesterol concentration being determined from the differ-
ence (total cholesterol - supernatant cholesterol).
Triacylglycerols were analysed with a fully automated enzymatic
method consisting of cleavage of the ester bonds and determination
of the free glycerol by colorimetric detection using glyceroU3-
phosphate oxidase, 4-chlorophenol, 4-aminophenazone and peroxi-
dase (Boehringer-Mannheim - GPO-PAP method).
Quantitative lipid electrophoresis was performed using the Rapi-
dophor electrophoresis system from Immuno, (Lipidophor ail in
12). After electrophoretic separation, the lipoproteins were precipi-
tated using a polyanionic solution followed by densitometric analy-
sis of the electropherogram.
Statistics
As the distribution of lipoprotein(a) values was highly skewed
(Kolmogorov-Smirnoff test), non-parametric statistics were used
throughout. The median was used as central tendency and relevant
percentiles as dispersion markers. The Mann-Whitney U-test was
used for the comparision of two independent variables, the
Kruskal-Wallis one way anlaysis of variance for the 14 groups fol-
lowed by the Nemenyi test to detect differences between any two
groups.
The data for the lipid analytes were checked for each analyte. The
Kolmogorov-Smirnobtest showed that the analyte groups taken as
a whole, irrespective of age and sex, were not normally distributed.
The number of data in each age group was, however, often too
small for a meaningful analysis of distribution, so that non-para-
metric statistics were performed, as for lipoprotein(a).
To compare the age groups of the patients in different clinics, para-
metric statistics were used as the data were normally distributed.
A one way analysis of variance was performed to detect differences
between the eight patient groups, followed by a modified least
squares difference analysis as described by Bonferroni. The median
and relevant percentiles were again used as markers of central ten-
dency and dispersion.
Box and whisker plots were used to display the data visually. The ·
interquartile range, 95% confidence limits, outliers (values lying
between 1.5 and 3 box-lengths above the 75th percentile) and ex-
treme values (more than 3 box-lengths above the 75th percentile)
were shown for each box and whisker plot.
Results
Distribution of lipoprotein(a) concentrations
The use of p-values for the inter-group comparisons has
been reserved only for statistically significant differ-
ences at the 5% and 1% levels/
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Figure 1 shows the distribution of median lipoprotein(a)
concentrations according to age and sex for the 18—100
year old persons. Table 1 shows the comparison between
mothers at birth and non-pregnant hospitalised women
as well as the renal insufficiency patients before haemo-
dialysis. Table 1 also shows the quartile and median val-
ues, as well as the range of concentrations for each age
group.
The median concentrations for males 'decline from a
maximum in persons aged between 60 and 69 years to
values similar to those in young children (4, 7) in those
above 80 years of age. The difference between the 60-
69 and 70-79 year old men was not statistically signifi-
cant, but it was significantly lower in the 80—89 year
old group (p < 0.05), compared with the 60-69 year
old group. The pattern in women is different, with the
highest values between 60 and 70 years, a decrease over
the next decade, a small, but not statistically significant,
increase between 80 and 90 years, and sharp decrease in
women above 90 years of age, although the latter group
was small (n = 5). In contrast to the men, the difference
between the 60—69 year old women was not signifi-
cantly different from the 80—89 year old group. There
was a marginal significant increase in women under 30
years of age compared with women aged between 60
and 69 years (p = 0.05).
In the 18—59 year old group, the following statistical
data were established. In the 18—29 year old women
there was no difference between lipoprotein(a) concen-
trations in healthy non-pregnant women and either
women at term, or women undergoing hospital treat-
ment.
The same was true for the groups of women aged 30—
39 years with the comparison between healthy non-preg-
nant women and women at term and those undergoing
hospital treatment (tab. 1).
As a result of these analyses, all data for women be-
tween 18 and 59 years of age were assessed according
to age, and independent of diagnosis.
There was no statistically significant difference in lipo-
protein(a) concentrations between healthy and hospitali-
sed males between 18 and 39 years of age so that no
differentiation between healthy individuals and those
undergoing hospital treatment was made. The data were
treated just as for the females, i. e. in groups according
to age only. The number of healthy men between 40 and
59 years was too small for a meaningful statistical analy-
sis.
There was an increase in lipoprotein(a) concentrations
in the 30—39 year old men compared with the 18-29
year old men, which was, however, not statistically sig-
nificant (p > 0.05). A significant difference was seen
when the 18—29 year old men were compared with 60—
69 year old men (p < 0.05), but there was no significant
difference when compared with the 40—49 and 50—59
year old men. There was no significant difference be-
tween the 30—39 year old men and the 40—49 year
old men.
There was no difference in lipoprotein (a) concentra-
tions in women between 18 and 29 and those between
30 and 39 years of age. There was a significant differ-
ence, however, between the 18 and 29 year old women
and the 60—69 year old women p = 0.05) but not
between the 18 and 29 old women and the 50-59
year old women.
There was no significant difference in lipoprotein(a)
concentrations between men and women aged 18—79
years. The levels in men between 80 and 90 years of age
were significantly lower than in women (p = 0.01). The
number of subjects above 90 years of age was too small
for statistical analysis (2 men and 5 women).
18-29 30-39 40-49 60-59 60-69 70-79 80-89 90-100
Age [a]
Fig. 1 Distribution of median lipoprotein(a) concentrations in the groups are shown on the abscissa, the median concentrations for
serum from 1967 adults aged between 18 and 100 years. The age males Ü, and females ·, on the ordinate.
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The differences in lipoprotein(a) concentrations in the
dialysis patients were unexpected (tab. 1). In women be-
tween 30 and 74 years of age undergoing dialysis, the
serum lipoprotein(a) concentrations were significantly
higher than in men of the corresponding age group
(p < 0.01 in the age groups 30-44, 45-59 and 60-
74 a).
Figure 2 shows the distribution of values in the 14 age
groups studied. Due to the large spread of results it is
small wonder that the differences in the median concen-
trations shown in figure 1 are rarely statistically signifi-
cant.
Distribution of age groups and lipoprotein(a)
concentrations according to clinics
Figure 3a shows the distribution of the ages in the dif-
ferent groups according to the clinic in which the pa-
tients were undergoing treatment.
• f
The women on the maternity ward were significantly
younger (median age 26 a) (p < 0.05—< 0.01) than in
the other seven groups. The hospital staff attending the
annual check-up were younger than all groups except
those on the maternity ward (median age 3la)
(p < 0.01). Table 2 shows the median ages of each
Tab. 1 Quartile values for lipoprotein(a) concentrations in the different groups studied.
Lipoprotein(a) (mg/1)
Lowest value 1st Quartile Median 3rd Quartile Highest value
Males
<30 years '·
30-39
40-49
50-59
60-69
70-79
80-89
>90
Females
<30 years
30-39
40-49
50-59
60-69
70-79
80-89
>90
5.9
2.6
2.7
3.5
2.0
1.8
4.0
31
1.0
3.4
1.0
6.5
2.2
2.8
4.3
9.0
33
35
35
37
43
63
39
41
36
56
77
38
46
40
54
118
109
121
146
116
56
48
102
108
100
135
148
84
88
34
150
424
368
262
359
374
102
286
388
494
568
370
253
211
1000
2576
1420
1069
2800
1907
521
64
3149
1630
2589
1976
1134
1345
1000
68
80
146
125
87
128
65
41
2
517
224
51
83
82
87
86
s
Maternity patients
<30
30-39
Female patients
<30
30-39
Healthy females
<30
30-39
Males-dialysis
<30
30-44
45-59
60-74
75-89
Females-dialysis
<30
30-44
45-59
60-74
75-89
1.0
3.4
9.0
5.0
8.0
5.7
21
8.0
3.5
1.8
14
3.2
17
18
2.8
11
40
44
30
23
42
41
36
57
20
64
54
92
142
31
99
109
94
108
96
108
80
116
140
123
89
107
250
222
290
60
271
307
244
445
242
285
318
320
319
289
502
577
511
138
3149
1630
1455
977
1256
1614
502
1099
1002
1907
880
535
2589
1976
1226
1164
347
162
54
50
60
54
6
27
36
32
13
3
13
28
36
19
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group, together with the relationship between the mean
and the median ages.
The average age of the patients attending the internal
medical and urological clinics was higher than in the
other groups.
Figure 3b shows the lipoprotein(a) concentrations in the
same groups. The lipoprotein(a) concentrations in the
haemodialysis patients (median 183 mg/1) were margin-
ally higher (p = 0.05) than in those patients on the in-
ternal medical wards (median 100 mg/1). Again, the
wide range of results reflects the minimal statistically
significant difference between the groups. Table 2 shows
the median lipoprotein(a) concentration for each group
together with the value mean/median as an index of
skewness of the data.
The difference in the number of subjects in figure 2
(n = 1802) and in figures 3a and 3b (n = 1756) is due
to out-patients who could not be assigned to a definite
clinic.
Distribution of cholesterol and
triacylglycerols
A direct comparison of these groups of patients with
those above is not statistically valid, as other patients
were examined, who had had a serum lipid request,
either directly in serum or as a lipid electrophoresis.
Table 3 summarises the data shown below. Emphasis
was laid on the ratio between low density- and high
density lipoprotein cholesterol and on triacylglycerol
levels in the three groups of patients studied.
These patients were first analysed as a single group,
with the division between those under 60 and those
over 60 years of age, according to sex, then in appro-
priate cases according to whether they had normal or
abnormal lipid electrophoresis. Significant differences
were found at the p < 0.05 level in the following
cases. Total cholesterol (n = 1898) (fig. 4a) was higher
in females between 30 and 39 and between 50 and
79 years of age, when compared with females under
30, and higher in males aged between 30 and 69
when compared with males between 70 and 89 years
of age.
Triacylglycerols (n = 1966) (fig. 4b) were higher in
males between 40—59 than in males aged 70—89, and
higher in females aged between 60 and 69 years com-
pared with females under 30.
HDL-cholesterol (n = 1655) (fig. 4c) was higher in men
aged under 30 and between 40—59 compared with men
aged between 70 and 89 years 60—69. In women, HDL-
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Age groups studied
Fig. 2 The distribution of the lipoprotein(a) values of the 7 male
(m) and female (f) age groups studied are shown using the box and
whisker plot method.
The box and whisker plots show the data as follows: the box con-
tains the results within the interquartile range, the bar within the
box, the median value. The whiskers enclose the 95% confidence
range. Outliers (between 1.5 and 3 box lengths above (or below)
the box-limits) are shown as open circles, extreme values (values
lying more than three box lengths from the box-limits) as asterisks.
N denotes the number in each group.
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cholesterol was higher in women aged 50 to 59 than in LDL-cholesterol (n = 1646) (fig. 4d) was higher in men
women aged 60-89 years. aged 50-59 compared with men aged 80-89 years. In
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Fig. 3 a) Box and whisker plots
a) for the distribution of the age groups of the patients in the lipo-
protein(a) group, according to the clinic in which they were being
treated, the clinics being listed on the abscissa.
b) for the distribution of lipoprotein(a) concentrations.
The box and whisker plots show the data as follows: the box con-
tains the results within the interquartile range, the bar within the
box, the median value. The whiskers enclose the 95% confidence
range. Outliers (between 1.5 and 3 box lengths above (or below)
the box-limits) are shown as open circles, extreme values (values
lying more than three box lengths from the box-limits) as asterisks.
N 'denotes the number in each group.
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Tab. 2 Frequency distribution of the patients according to the
clinics requesting the analysis. In addition, age and median lipopro-
tein(a) (Lp(a)) values are given.
a) Lipoprotein(a) study
Clinic
Internal medicine
Surgical
Maternity
Nephrology/Dialysis
Psychiatry
Varia
Urology
Check-up
Frequency
(%ofall
patients)
22.6
8.0
35.2
6.6
10.5
4.6
3.1
9.4
Median
age
(years)
66
55
26
56
38
46
69
32
Median
Lp(a)
(mg/1)
100
121
103
183
103
107
128
100
b) Lipid analytes study
Clinic
Internal medicine
Nephrology/Dialysis
Varia
Outpatients
Frequency
(%ofall
patients)
38.3
49.9
6.5
5.2
Median
age
(years)
58
54
31
48
women, higher levels of LDL-cholesterol were observed
in women aged 50—69 years compared with women
aged under 30 and between 80 and 89 years of age.
The ratio LDL/HDL-cholesterol (n = 1686) (fig. 4e)
showed no significant differences.
The numbers in parentheses for each analyte show the
number of data used in the calculations.
In the patients with normal lipid electrophoresis patterns
(tab. 3) the number of patients in each age group was
too small for separate statistical analysis. The only point
to note was that the women were on average (median
age) over 10 years older than the men. In the men with
pathological lipid electrophoresis patterns (tab. 3), the
ratio LDL/HDL-cholesterol followed a similar pattern to
that for lipoprotein(a), but with peaks occurring a decade
earlier. Cholesterol levels showed a different pattern,
without pronounced peaks. In the women with a patho-
logical lipid electrophoresis (tab. 3), the ratio LDL/
HDL-cholesterol followed a similar, even if less pro-
nounced pattern as in the men. As in the men, the cho-
lesterol levels showed little or no correlation with age,
but were on average lower in women. Triacylglycerols
were higher in men under 70 than in women, and lower
in men than in women in those over 70.
As was to be -expected, the patients with pathological
electrophoresis patterns had significantly higher concen-
trations of all lipid analytes except for HDL-cholesterol,
where there was no significant difference between any
of the groups.
The separate groups are shown in table 3 for completion
of data presentation, although only those data in figures
4a-4e, i. e. from the combined groups, are used for vi-
sual presentation.
Age and cl inic attendance in the lipid groups
Tables 2 and 3 show the distribution of the ages of those
included in the lipid patient groups. Whereas the selec-
tion of the patients for the lipid study group was taken
from the requests for lipid-analysis, those from the lipo-
protein(a) group were selected to give more or less equal
numbers in each patient group, and were selected inde-
pendently of the primary diagnosis. This gave rise to the
different proportions of samples from each clinic. The
majority of samples in the lipid group came from the
internal medical wards (38.3%) and from the nephrology
and dialysis clinics (49.9%). The number of out-patients
(5.3%) and all other wards together (6.5%) account for
the remaining patients. The median age of the lipid-pa-
tients was not different for the nephrology/dialysis pa-
tients, and was slightly lower for the internal medicine
patients (tab. 2).
Discussion
Although the persons in both study groups were not
identical, the number of observations made allows for a
statistical evaluation of analytes in hospitalised patients
for the analytes and persons tested. The German Federal
Bureau of Statistics confirms early that around half the
deaths registered are due to cardiovascular disease and
atherosclerosis (3). Several studies have associated se-
rum cholesterol levels with risk of cardiac disease
(8—12) and national studies have been and are being
carried out in industrialised society to educate the pop-
ulation of the dangers of high serum cholesterol (9, 12—
14) and with the aim of reducing serum lipids.
The role of lipoprotein(a) as an independent risk factor
in atherogenesis is generally accepted (15), but because
it is at present not possible to reduce the concentrations
of this analyte in blood over extended periods of time,
little has been undertaken except heparin extracorporal
LDL precipitation (HELP) apheresis, which has to be
carried out regularly to have any significant effect (16).
Short and medium term effects on reducing serum lipo-
protein(a) have been reported using niacin (17), tamoxi-
fen (18) and plant extracts (19) and in non-treated hy-
perthyroidism (20). Hydroxymethylglutaryl-CoA reduc-
tase inhibitors (17) and fibrous diets (21), although effi-
cient in reducing LDL-cholesterol levels, do not
Bur J Clin Chem Clio Biochem 1995; 33 (No 12)
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significantly alter lipoprotein(a) concentrations, again
highlighting the different metabolic pathway of the latter.
The difference in behaviour of lipoprotein(a), choles-
terol fractions and triacylglycerols in the different age
groups support the claim that lipoprotein(a) is a risk
factor which is independent of that of total cholesterol,
and LDL-cholesterol. The median levels of lipopro-
tein(a) during life reflect the major occurrence of cardiac
disease, with a small peak in men between 30 and 40,
and a maximum between 60 and 70 years of age, and in
women a relatively broad peak after the menopause, i. e.
Tab. 3 Median values of "classical" lipid analytes in men and women with lipid-requests.
Males
<30 years
30-39
40-49
50-59
60-69
70-79
80-89
>90
Females
<30 years
30-39
40-49
50-59
60-69
70-79
80-89
>90
Males — Normal
<30 years
30-39
40-49
50-59
60-69
70-79
80-89
Cholesterol
(mmol/1)
6.20
6.50
6.95
6.90
6.60
6.20
5.50
5.20
5.90
6.60
6.60
7.20
7.00
6.70
6.30
6.60
electrophoretic pattern
4.90
4.45
4.25
4.90
5.50
5.20
4.70
Triacylglycerols
(mmol/1)
1.90
2.70
2.40
2.50
2.10
2.00
1.60
2.25
1.20
2.00
2.20
2.10
2.20
2.30
1.85
2.90
.80
.35
.05
.80
.60
2.70
2.00
HDL-cholesterol
(mmol/1)
1.40
1.10
1.20
1.10
1.00
0.90
0.90
1.00
.20
.30
.32
.38
.10
.10
1.00
1.10
.50
.05
.40
.30
.30
.35
.30
LDL-cholesterol
(mmol/1)
3.90
4.32
4.80
4.70
4.70
4.40
3.42
3.20
4.05
4.60
4.50
5.10
5.00
4.70
3.80
4.70
3.30
3.25
2.65
3.50
3.80
3.50
3.00
LDL-cholesterol
HDL-cholesterol
3.03
4.57
3.60
4.35
4.45
4.98
3.78
3.20
3.37
3.76
3.55
3.87
4.50
4.08
4.05
4.27
2.29
2.60
1.98
2.29
2.92
2.70
2.31
n
56
92
140
230
373
153
36
2
51
50
62
187
315
181
102
4
5
10
12
19
9
2
2
Females - Normal electrophoretic pattern
<30 years
30-39
40-49
50-59
60-69
70-79
80-89
4.20
5.95
5.55
5.25
4.65
4.35
5.10
0.90
2.00
1.30
1.75
1.35
2.30
1.30
1.20
2.05
.90
.45
.10
.20
.20
2.90
3.65
3.25
3.55
3.30
3.00
3.50
2.33
1.80
1.76
2.44
3.00
3.08
2.91
8
2
2
3
10
6
6
Males - Pathological electrophoretic pattern
<30 years
30-39
40-49
50-59
60-69
70-79
80-89
7.65
8.30
7.80
8.00
7.50
6.70
7.00
3.30
3.65
3.75
3.10
3.35
2.50
1.50
.05
.00
.05
.15
.10
.00
.60
4.40
6.45
5.55
5.90
5.30
4.70
5.10
4.30
5.81
4.00
5.06
5.09
3.82
3.19
21
47 N
74
85
72
17
2
Females - Pathological electrophoretic pattern
<30 years
30-39
40-49
50-59
60-69
70-79
80-89
6.20
7.10
7.55
7.50
7.80
7.55
7.00
1.20
2.20
2.35
2.30
2.80
2.90
3.00
1.00
1.25
1.30
1.40
1.30n
1.35
0.95
4.70
4.80
5.60
5.50
5.80
5.30
4.95
3.97
4.29
3.70
4.40
4.46
3.93
5.51
13
28
22
95
67
38
9
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between 50 and 70 years of age. A second small peak
in women between 80 and 90 years of age has been
observed, although the significance of this must be fur-
ther investigated and may very well be regional in na-
ture. One thing is certain from this study, and that is,
those who survive to very old age have median lipopro-
tein(a) levels similar to those found in children and ado-
lescents (4, 7). This again supports the fact that low
levels of lipoprotein(a) are of no significant additional
risk for myocardial infarction.
The only indicator from the 'traditional' lipid metabo-
lites which reflects the risk of cardiovascular disease in
E
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Fig. 4 Box and whisker plots for the lipid analysis observed in a) total cholesterol
the 2037 patients with lipid requests. b) triacylglycerols
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the patients with suspected or confirmed lipid disorders
was the ratio LDL/HDL-cholesterol, although no statis-
tically significant age-related differences were found
with this quotient. The usefulness of this ratio is perhaps
to be expected, as the negative (atherogenic) effects of
LDL-cholesterol are further attenuated by a reduction in
the partly atheroprotective effects of HDL-cholesteroI.
The use of LDL/HDL2 or LDL/HDL3 ratios appears to
be too early, as the results on the atheroprotective effects
of HDL2 and HDL3 are controversial (22).
The fact that the pattern for lipoprotein(a) compared
with age, irrespective of the state of the individual (in
38 36 76 48 122 52 204 179 281 234 120 148
c)
Age groups studied
122 53 204 179 280 234 117 143
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.
n d Whisker pbts for the lipid
the 2037 patients with lipid requests.
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d) LDL-cholesterol
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Fig. 4 Box and whisker plots for the lipid analysis observed in
the 2037 patients with lipid requests,
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The data for figure 4e was from each individual LDL/HDL ratio,
so that the median value shown may not be identical to that ob-
tained by dividing median LDL-cholesterol by median HDL-cho-
lesterol values.
The box and whisker plots show the data as follows: the box con-
tains the results within the interquartile range, the bar within the
box, the median value. The whiskers enclose the 95% confidence
range. Outliers (between 1.5 and 3 box lengths above (or below)
the box-limits) are shown as open circles, extreme values (values
lying more than three box lengths from the box-limits) as asterisks.
N denotes the number in each group.
this study no difference between mothers at birth, hospi-
talised women of the same age group and healthy non-
pregnant controls) gives support to the genetic disposi-
tion rather than to acquired risk factors, as is the case for
cholesterol-fractions in individuals not suffering from a
genetic defect in cholesterol metabolism.
The findings that female haemodialysis patients above
30 years of age have significantly higher levels of lipo-
protein(a) in serum than men of the corresponding age
was unexpected and must be studied more deeply, espe-
cially in the light of the negative effects of haemodialy-
sis, i. e. the increase of serum lipoprotein(a) concentra-
tions during dialysis, both when using chronic haemodi-
alysis (23, 24) or continuous ambulatory peritoneal dial-
ysis (25).
As there is no long-term treatment for increased lipo-
protein(a) levels, perhaps with the exception of HELP
apheresis, the only course of action in such individ-
uals, especially children, is to minimise the other car-
diovascular risk factors as far as is possible (26).
Whether there is an influence of the genetically deter-
mined apolipoprotein(a) forms on the risk of cardio-
vascular disease has still to be confirm, although re-
sults on haemodialysis patients tend to support such a
claim (27).
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